{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T18:32:43Z","timestamp":1793039563842,"version":"4.5.0"},"reference-count":70,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T00:00:00Z","timestamp":1747180800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T00:00:00Z","timestamp":1747180800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"National Cancer Center Research Grant","award":["2110262"],"award-info":[{"award-number":["2110262"]}]},{"name":"National Cancer Center Research Grant","award":["2310670"],"award-info":[{"award-number":["2310670"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Mol Biol Lett"],"DOI":"10.1186\/s11658-025-00735-5","type":"journal-article","created":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T04:04:10Z","timestamp":1747195450000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Narciclasine enhances cisplatin-induced apoptotic cell death by inducing unfolded protein response-mediated regulation of NOXA and MCL1"],"prefix":"10.1186","volume":"30","author":[{"given":"Ji Hae","family":"Lee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seung Hee","family":"Seo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaegal","family":"Shim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong-Nyun","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-5818-0021","authenticated-orcid":false,"given":"Kyungsil","family":"Yoon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,14]]},"reference":[{"issue":"1","key":"735_CR1","doi-asserted-by":"publisher","first-page":"17","DOI":"10.3322\/caac.21763","volume":"73","author":"RL Siegel","year":"2023","unstructured":"Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. CA Cancer J Clin. 2023;73(1):17\u201348.","journal-title":"CA Cancer J Clin"},{"key":"735_CR2","unstructured":"SEER*Explorer: An interactive website for SEER cancer statistics. Surveillance Research Program, National Cancer Institute, Data source(s): SEER Incidence Data, November 2022 Submission (1975\u20132020), SEER 22 registries, 2023. 2023. https:\/\/seer.cancer.gov\/statistics-network\/explorer\/. Accessed 31 Mar 2024."},{"issue":"10299","key":"735_CR3","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/S0140-6736(21)00312-3","volume":"398","author":"AA Thai","year":"2021","unstructured":"Thai AA, Solomon BJ, Sequist LV, Gainor JF, Heist RS. Lung cancer. Lancet. 2021;398(10299):535\u201354.","journal-title":"Lancet"},{"issue":"1","key":"735_CR4","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1186\/s13045-023-01436-2","volume":"16","author":"SM Liu","year":"2023","unstructured":"Liu SM, Zheng MM, Pan Y, Liu SY, Li Y, Wu YL. Emerging evidence and treatment paradigm of non-small cell lung cancer. J Hematol Oncol. 2023;16(1):40.","journal-title":"J Hematol Oncol"},{"issue":"12","key":"735_CR5","doi-asserted-by":"publisher","first-page":"1356","DOI":"10.1200\/JCO.21.02528","volume":"40","author":"ME Daly","year":"2022","unstructured":"Daly ME, Singh N, Ismaila N, Antonoff MB, Arenberg DA, Bradley J, et al. Management of stage III non-small-cell lung cancer: ASCO guideline. J Clin Oncol. 2022;40(12):1356\u201384.","journal-title":"J Clin Oncol"},{"issue":"28","key":"735_CR6","doi-asserted-by":"publisher","first-page":"3310","DOI":"10.1200\/JCO.22.00824","volume":"40","author":"N Singh","year":"2022","unstructured":"Singh N, Temin S, Baker S Jr, Blanchard E, Brahmer JR, Celano P, et al. Therapy for stage IV non-small-cell lung cancer with driver alterations: ASCO living guideline. J Clin Oncol. 2022;40(28):3310\u201322.","journal-title":"J Clin Oncol"},{"issue":"28","key":"735_CR7","doi-asserted-by":"publisher","first-page":"3323","DOI":"10.1200\/JCO.22.00825","volume":"40","author":"N Singh","year":"2022","unstructured":"Singh N, Temin S, Baker S Jr, Blanchard E, Brahmer JR, Celano P, et al. Therapy for stage IV non-small-cell lung cancer without driver alterations: ASCO living guideline. J Clin Oncol. 2022;40(28):3323\u201343.","journal-title":"J Clin Oncol"},{"issue":"4","key":"735_CR8","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1016\/j.annonc.2022.12.013","volume":"34","author":"LE Hendriks","year":"2023","unstructured":"Hendriks LE, Kerr KM, Menis J, Mok TS, Nestle U, Passaro A, et al. Non-oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol. 2023;34(4):358\u201376.","journal-title":"Ann Oncol"},{"issue":"4","key":"735_CR9","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1016\/j.annonc.2022.12.009","volume":"34","author":"LE Hendriks","year":"2023","unstructured":"Hendriks LE, Kerr KM, Menis J, Mok TS, Nestle U, Passaro A, et al. Oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol. 2023;34(4):339\u201357.","journal-title":"Ann Oncol"},{"issue":"1","key":"735_CR10","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1186\/s12935-023-02990-y","volume":"23","author":"M Araghi","year":"2023","unstructured":"Araghi M, Mannani R, Heidarnejad Maleki A, Hamidi A, Rostami S, Safa SH, et al. Recent advances in non-small cell lung cancer targeted therapy; an update review. Cancer Cell Int. 2023;23(1):162.","journal-title":"Cancer Cell Int"},{"issue":"1","key":"735_CR11","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1080\/07357907.2022.2119479","volume":"41","author":"F Abu Rous","year":"2023","unstructured":"Abu Rous F, Singhi EK, Sridhar A, Faisal MS, Desai A. Lung cancer treatment advances in 2022. Cancer Invest. 2023;41(1):12\u201324.","journal-title":"Cancer Invest"},{"issue":"13","key":"735_CR12","doi-asserted-by":"publisher","first-page":"7241","DOI":"10.3390\/ijms23137241","volume":"23","author":"R Ali","year":"2022","unstructured":"Ali R, Aouida M, Alhaj Sulaiman A, Madhusudan S, Ramotar D. Can cisplatin therapy be improved? Pathways that can be targeted. Int J Mol Sci. 2022;23(13):7241.","journal-title":"Int J Mol Sci"},{"key":"735_CR13","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.ctrv.2016.01.003","volume":"44","author":"DA Fennell","year":"2016","unstructured":"Fennell DA, Summers Y, Cadranel J, Benepal T, Christoph DC, Lal R, et al. Cisplatin in the modern era: the backbone of first-line chemotherapy for non-small cell lung cancer. Cancer Treat Rev. 2016;44:42\u201350.","journal-title":"Cancer Treat Rev"},{"issue":"1","key":"735_CR14","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1007\/s13659-020-00293-7","volume":"11","author":"M Huang","year":"2021","unstructured":"Huang M, Lu JJ, Ding J. Natural products in cancer therapy: past, present and future. Nat Prod Bioprospect. 2021;11(1):5\u201313.","journal-title":"Nat Prod Bioprospect"},{"issue":"16","key":"735_CR15","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.1055\/s-0042-115034","volume":"82","author":"R F\u00fcrst","year":"2016","unstructured":"F\u00fcrst R. Narciclasine\u2014an Amaryllidaceae alkaloid with potent antitumor and anti-inflammatory properties. Planta Med. 2016;82(16):1389\u201394.","journal-title":"Planta Med"},{"issue":"9","key":"735_CR16","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1593\/neo.07535","volume":"9","author":"P Dumont","year":"2007","unstructured":"Dumont P, Ingrassia L, Rouzeau S, Ribaucour F, Thomas S, Roland I, et al. The Amaryllidaceae isocarbostyril narciclasine induces apoptosis by activation of the death receptor and\/or mitochondrial pathways in cancer cells but not in normal fibroblasts. Neoplasia. 2007;9(9):766\u201376.","journal-title":"Neoplasia"},{"issue":"1","key":"735_CR17","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1186\/s40360-021-00537-3","volume":"22","author":"Y Yuan","year":"2021","unstructured":"Yuan Y, He X, Li X, Liu Y, Tang Y, Deng H, et al. Narciclasine induces autophagy-mediated apoptosis in gastric cancer cells through the Akt\/mTOR signaling pathway. BMC Pharmacol Toxicol. 2021;22(1):70.","journal-title":"BMC Pharmacol Toxicol"},{"issue":"2","key":"735_CR18","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1002\/med.21253","volume":"33","author":"G Van Goietsenoven","year":"2013","unstructured":"Van Goietsenoven G, Mathieu V, Lefranc F, Kornienko A, Evidente A, Kiss R. Narciclasine as well as other Amaryllidaceae isocarbostyrils are promising GTP-ase targeting agents against brain cancers. Med Res Rev. 2013;33(2):439\u201355.","journal-title":"Med Res Rev"},{"issue":"11","key":"735_CR19","doi-asserted-by":"publisher","first-page":"4575","DOI":"10.1096\/fj.10-162263","volume":"24","author":"G Van Goietsenoven","year":"2010","unstructured":"Van Goietsenoven G, Hutton J, Becker JP, Lallemand B, Robert F, Lefranc F, et al. Targeting of eEF1A with Amaryllidaceae isocarbostyrils as a strategy to combat melanomas. FASEB J. 2010;24(11):4575\u201384.","journal-title":"FASEB J"},{"key":"735_CR20","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1016\/j.omto.2021.12.025","volume":"24","author":"C Lv","year":"2022","unstructured":"Lv C, Huang Y, Huang R, Wang Q, Zhang H, Jin J, et al. Narciclasine targets STAT3 via distinct mechanisms in tamoxifen-resistant breast cancer cells. Mol Ther Oncolytics. 2022;24:340\u201354.","journal-title":"Mol Ther Oncolytics"},{"issue":"5468","key":"735_CR21","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1126\/science.288.5468.1053","volume":"288","author":"E Oda","year":"2000","unstructured":"Oda E, Ohki R, Murasawa H, Nemoto J, Shibue T, Yamashita T, et al. Noxa, a BH3-only member of the Bcl-2 family and candidate mediator of p53-induced apoptosis. Science. 2000;288(5468):1053\u20138.","journal-title":"Science"},{"issue":"3","key":"735_CR22","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1038\/s41580-018-0089-8","volume":"20","author":"R Singh","year":"2019","unstructured":"Singh R, Letai A, Sarosiek K. Regulation of apoptosis in health and disease: the balancing act of BCL-2 family proteins. Nat Rev Mol Cell Biol. 2019;20(3):175\u201393.","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"18","key":"735_CR23","doi-asserted-by":"publisher","first-page":"3667","DOI":"10.1038\/emboj.2011.307","volume":"30","author":"A Strasser","year":"2011","unstructured":"Strasser A, Cory S, Adams JM. Deciphering the rules of programmed cell death to improve therapy of cancer and other diseases. EMBO J. 2011;30(18):3667\u201383.","journal-title":"EMBO J"},{"issue":"2","key":"735_CR24","doi-asserted-by":"publisher","first-page":"256","DOI":"10.3390\/life12020256","volume":"12","author":"R Roufayel","year":"2022","unstructured":"Roufayel R, Younes K, Al-Sabi A, Murshid N. BH3-only proteins Noxa and Puma are key regulators of induced apoptosis. Life. 2022;12(2):256.","journal-title":"Life"},{"issue":"3","key":"735_CR25","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1016\/j.bbrc.2011.08.118","volume":"413","author":"P Gomez-Bougie","year":"2011","unstructured":"Gomez-Bougie P, M\u00e9noret E, Juin P, Dousset C, Pellat-Deceunynck C, Amiot M. Noxa controls Mule-dependent Mcl-1 ubiquitination through the regulation of the Mcl-1\/USP9X interaction. Biochem Biophys Res Commun. 2011;413(3):460\u20134.","journal-title":"Biochem Biophys Res Commun"},{"key":"735_CR26","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.54954","volume":"9","author":"S Arai","year":"2020","unstructured":"Arai S, Varkaris A, Nouri M, Chen S, Xie L, Balk SP. MARCH5 mediates NOXA-dependent MCL1 degradation driven by kinase inhibitors and integrated stress response activation. Elife. 2020;9: e54954.","journal-title":"Elife"},{"issue":"24","key":"735_CR27","doi-asserted-by":"publisher","first-page":"36353","DOI":"10.18632\/oncotarget.9217","volume":"7","author":"W Nakajima","year":"2016","unstructured":"Nakajima W, Sharma K, Lee JY, Maxim NT, Hicks MA, Vu TT, et al. DNA damaging agent-induced apoptosis is regulated by MCL-1 phosphorylation and degradation mediated by the Noxa\/MCL-1\/CDK2 complex. Oncotarget. 2016;7(24):36353\u201365.","journal-title":"Oncotarget"},{"issue":"1","key":"735_CR28","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1186\/s13045-021-01079-1","volume":"14","author":"H Wang","year":"2021","unstructured":"Wang H, Guo M, Wei H, Chen Y. Targeting MCL-1 in cancer: current status and perspectives. J Hematol Oncol. 2021;14(1):67.","journal-title":"J Hematol Oncol"},{"issue":"10","key":"735_CR29","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1593\/neo.07589","volume":"9","author":"Y Mei","year":"2007","unstructured":"Mei Y, Xie C, Xie W, Tian X, Li M, Wu M. Noxa\/Mcl-1 balance regulates susceptibility of cells to camptothecin-induced apoptosis. Neoplasia. 2007;9(10):871\u201381.","journal-title":"Neoplasia"},{"issue":"6","key":"735_CR30","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1002\/1878-0261.12172","volume":"12","author":"K Sharma","year":"2018","unstructured":"Sharma K, Vu TT, Cook W, Naseri M, Zhan K, Nakajima W, et al. p53-independent Noxa induction by cisplatin is regulated by ATF3\/ATF4 in head and neck squamous cell carcinoma cells. Mol Oncol. 2018;12(6):788\u201398.","journal-title":"Mol Oncol"},{"issue":"8","key":"735_CR31","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1080\/14728222.2017.1349754","volume":"21","author":"JE Guikema","year":"2017","unstructured":"Guikema JE, Amiot M, Eldering E. Exploiting the pro-apoptotic function of NOXA as a therapeutic modality in cancer. Expert Opin Ther Targets. 2017;21(8):767\u201379.","journal-title":"Expert Opin Ther Targets"},{"issue":"6","key":"735_CR32","doi-asserted-by":"publisher","first-page":"802","DOI":"10.3390\/biom12060802","volume":"12","author":"M Yang","year":"2022","unstructured":"Yang M, Lu Y, Piao W, Jin H. The translational regulation in mTOR pathway. Biomolecules. 2022;12(6):802.","journal-title":"Biomolecules"},{"issue":"10","key":"735_CR33","doi-asserted-by":"publisher","first-page":"1374","DOI":"10.15252\/embr.201642195","volume":"17","author":"K Pakos-Zebrucka","year":"2016","unstructured":"Pakos-Zebrucka K, Koryga I, Mnich K, Ljujic M, Samali A, Gorman AM. The integrated stress response. EMBO Rep. 2016;17(10):1374\u201395.","journal-title":"EMBO Rep"},{"issue":"5453","key":"735_CR34","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1126\/science.287.5453.664","volume":"287","author":"F Urano","year":"2000","unstructured":"Urano F, Wang X, Bertolotti A, Zhang Y, Chung P, Harding HP, et al. Coupling of stress in the ER to activation of JNK protein kinases by transmembrane protein kinase IRE1. Science. 2000;287(5453):664\u20136.","journal-title":"Science"},{"issue":"2","key":"735_CR35","doi-asserted-by":"publisher","first-page":"156","DOI":"10.3390\/biomedicines9020156","volume":"9","author":"N Siwecka","year":"2021","unstructured":"Siwecka N, Rozpedek-Kaminska W, Wawrzynkiewicz A, Pytel D, Diehl JA, Majsterek I. The structure, activation and signaling of IRE1 and its role in determining cell fate. Biomedicines. 2021;9(2):156.","journal-title":"Biomedicines"},{"issue":"5","key":"735_CR36","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1016\/S1097-2765(00)00108-8","volume":"6","author":"HP Harding","year":"2000","unstructured":"Harding HP, Novoa I, Zhang Y, Zeng H, Wek R, Schapira M, et al. Regulated translation initiation controls stress-induced gene expression in mammalian cells. Mol Cell. 2000;6(5):1099\u2013108.","journal-title":"Mol Cell"},{"key":"735_CR37","doi-asserted-by":"publisher","DOI":"10.1016\/j.redox.2018.11.005","volume":"25","author":"Z Zhang","year":"2019","unstructured":"Zhang Z, Zhang L, Zhou L, Lei Y, Zhang Y, Huang C. Redox signaling and unfolded protein response coordinate cell fate decisions under ER stress. Redox Biol. 2019;25: 101047.","journal-title":"Redox Biol"},{"issue":"7","key":"735_CR38","doi-asserted-by":"publisher","first-page":"4252","DOI":"10.1074\/jbc.M705951200","volume":"283","author":"M Yokouchi","year":"2008","unstructured":"Yokouchi M, Hiramatsu N, Hayakawa K, Okamura M, Du S, Kasai A, et al. Involvement of selective reactive oxygen species upstream of proapoptotic branches of unfolded protein response. J Biol Chem. 2008;283(7):4252\u201360.","journal-title":"J Biol Chem"},{"issue":"5","key":"735_CR39","doi-asserted-by":"publisher","first-page":"705","DOI":"10.4161\/cbt.6.5.3963","volume":"6","author":"H Kadara","year":"2007","unstructured":"Kadara H, Lacroix L, Lotan D, Lotan R. Induction of endoplasmic reticulum stress by the pro-apoptotic retinoid N-(4-hydroxyphenyl)retinamide via a reactive oxygen species-dependent mechanism in human head and neck cancer cells. Cancer Biol Ther. 2007;6(5):705\u201311.","journal-title":"Cancer Biol Ther"},{"issue":"2","key":"735_CR40","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1111\/febs.14608","volume":"286","author":"A Almanza","year":"2019","unstructured":"Almanza A, Carlesso A, Chintha C, Creedican S, Doultsinos D, Leuzzi B, et al. Endoplasmic reticulum stress signaling\u2014from basic mechanisms to clinical applications. FEBS J. 2019;286(2):241\u201378.","journal-title":"FEBS J"},{"issue":"11","key":"735_CR41","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1101\/gad.992302","volume":"16","author":"H Nishitoh","year":"2002","unstructured":"Nishitoh H, Matsuzawa A, Tobiume K, Saegusa K, Takeda K, Inoue K, et al. ASK1 is essential for endoplasmic reticulum stress-induced neuronal cell death triggered by expanded polyglutamine repeats. Genes Dev. 2002;16(11):1345\u201355.","journal-title":"Genes Dev"},{"issue":"45","key":"735_CR42","doi-asserted-by":"publisher","first-page":"46384","DOI":"10.1074\/jbc.M403568200","volume":"279","author":"JH Hung","year":"2004","unstructured":"Hung JH, Su IJ, Lei HY, Wang HC, Lin WC, Chang WT, et al. Endoplasmic reticulum stress stimulates the expression of cyclooxygenase-2 through activation of NF-kappaB and pp38 mitogen-activated protein kinase. J Biol Chem. 2004;279(45):46384\u201392.","journal-title":"J Biol Chem"},{"key":"735_CR43","doi-asserted-by":"publisher","DOI":"10.1016\/j.phymed.2020.153399","volume":"80","author":"Q Zhao","year":"2021","unstructured":"Zhao Q, Bi Y, Guo J, Liu Y, Zhong J, Liu Y, et al. Effect of pristimerin on apoptosis through activation of ROS\/ endoplasmic reticulum (ER) stress-mediated noxa in colorectal cancer. Phytomedicine. 2021;80: 153399.","journal-title":"Phytomedicine"},{"issue":"24","key":"735_CR44","doi-asserted-by":"publisher","first-page":"13956","DOI":"10.1073\/pnas.96.24.13956","volume":"96","author":"P Kovarik","year":"1999","unstructured":"Kovarik P, Stoiber D, Eyers PA, Menghini R, Neininger A, Gaestel M, et al. Stress-induced phosphorylation of STAT1 at Ser727 requires p38 mitogen-activated protein kinase whereas IFN-gamma uses a different signaling pathway. Proc Natl Acad Sci USA. 1999;96(24):13956\u201361.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"7","key":"735_CR45","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1093\/carcin\/bgh115","volume":"25","author":"Y Zhang","year":"2004","unstructured":"Zhang Y, Cho YY, Petersen BL, Zhu F, Dong Z. Evidence of STAT1 phosphorylation modulated by MAPKs, MEK1 and MSK1. Carcinogenesis. 2004;25(7):1165\u201375.","journal-title":"Carcinogenesis"},{"issue":"8","key":"735_CR46","doi-asserted-by":"publisher","first-page":"1427","DOI":"10.1016\/j.biotechadv.2016.11.002","volume":"34","author":"EC Costa","year":"2016","unstructured":"Costa EC, Moreira AF, de Melo-Diogo D, Gaspar VM, Carvalho MP, Correia IJ. 3D tumor spheroids: an overview on the tools and techniques used for their analysis. Biotechnol Adv. 2016;34(8):1427\u201341.","journal-title":"Biotechnol Adv"},{"key":"735_CR47","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.ddtec.2017.03.002","volume":"23","author":"S Sant","year":"2017","unstructured":"Sant S, Johnston PA. The production of 3D tumor spheroids for cancer drug discovery. Drug Discov Today Technol. 2017;23:27\u201336.","journal-title":"Drug Discov Today Technol"},{"issue":"3","key":"735_CR48","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1016\/j.bbrc.2020.08.075","volume":"533","author":"M Muguruma","year":"2020","unstructured":"Muguruma M, Teraoka S, Miyahara K, Ueda A, Asaoka M, Okazaki M, et al. Differences in drug sensitivity between two-dimensional and three-dimensional culture systems in triple-negative breast cancer cell lines. Biochem Biophys Res Commun. 2020;533(3):268\u201374.","journal-title":"Biochem Biophys Res Commun"},{"issue":"5","key":"735_CR49","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1038\/s41388-018-0479-6","volume":"38","author":"SQ Liang","year":"2019","unstructured":"Liang SQ, B\u00fchrer ED, Berezowska S, Marti TM, Xu D, Froment L, et al. mTOR mediates a mechanism of resistance to chemotherapy and defines a rational combination strategy to treat KRAS-mutant lung cancer. Oncogene. 2019;38(5):622\u201336.","journal-title":"Oncogene"},{"issue":"11","key":"735_CR50","doi-asserted-by":"publisher","first-page":"1521","DOI":"10.3390\/biom10111521","volume":"10","author":"JH Lee","year":"2020","unstructured":"Lee JH, Park SY, Hwang W, Sung JY, Cho ML, Shim J, et al. Isoharringtonine induces apoptosis of non-small cell lung cancer cells in tumorspheroids via the intrinsic pathway. Biomolecules. 2020;10(11):1521.","journal-title":"Biomolecules"},{"issue":"D1","key":"735_CR51","doi-asserted-by":"publisher","first-page":"D941","DOI":"10.1093\/nar\/gky1015","volume":"47","author":"JG Tate","year":"2018","unstructured":"Tate JG, Bamford S, Jubb HC, Sondka Z, Beare DM, Bindal N, et al. COSMIC: the catalogue of somatic mutations in cancer. Nucleic Acids Res. 2018;47(D1):D941\u20137.","journal-title":"Nucleic Acids Res"},{"issue":"7","key":"735_CR52","doi-asserted-by":"publisher","first-page":"2200","DOI":"10.1073\/pnas.0807611106","volume":"106","author":"Q Wang","year":"2009","unstructured":"Wang Q, Mora-Jensen H, Weniger MA, Perez-Galan P, Wolford C, Hai T, et al. ERAD inhibitors integrate ER stress with an epigenetic mechanism to activate BH3-only protein NOXA in cancer cells. Proc Natl Acad Sci USA. 2009;106(7):2200\u20135.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"1","key":"735_CR53","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1084\/jem.20030613","volume":"199","author":"JY Kim","year":"2004","unstructured":"Kim JY, Ahn HJ, Ryu JH, Suk K, Park JH. BH3-only protein Noxa is a mediator of hypoxic cell death induced by hypoxia-inducible factor 1alpha. J Exp Med. 2004;199(1):113\u201324.","journal-title":"J Exp Med"},{"issue":"7","key":"735_CR54","doi-asserted-by":"publisher","first-page":"5945","DOI":"10.1074\/jbc.M406661200","volume":"280","author":"M Flinterman","year":"2005","unstructured":"Flinterman M, Guelen L, Ezzati-Nik S, Killick R, Melino G, Tominaga K, et al. E1A activates transcription of p73 and Noxa to induce apoptosis. J Biol Chem. 2005;280(7):5945\u201359.","journal-title":"J Biol Chem"},{"issue":"4","key":"735_CR55","doi-asserted-by":"publisher","first-page":"539","DOI":"10.3390\/genes12040539","volume":"12","author":"W Nakajima","year":"2021","unstructured":"Nakajima W, Miyazaki K, Asano Y, Kubota S, Tanaka N. Kr\u00fcppel-like factor 4 and its activator APTO-253 induce NOXA-mediated, p53-independent apoptosis in triple-negative breast cancer cells. Genes. 2021;12(4):539.","journal-title":"Genes"},{"key":"735_CR56","doi-asserted-by":"publisher","first-page":"556","DOI":"10.3389\/fendo.2020.00556","volume":"11","author":"HC Ku","year":"2020","unstructured":"Ku HC, Cheng CF. Master regulator activating transcription factor 3 (ATF3) in metabolic homeostasis and cancer. Front Endocrinol. 2020;11:556.","journal-title":"Front Endocrinol"},{"issue":"13","key":"735_CR57","doi-asserted-by":"publisher","first-page":"2425","DOI":"10.1038\/sj.emboj.7600712","volume":"24","author":"C Yan","year":"2005","unstructured":"Yan C, Lu D, Hai T, Boyd DD. Activating transcription factor 3, a stress sensor, activates p53 by blocking its ubiquitination. EMBO J. 2005;24(13):2425\u201335.","journal-title":"EMBO J"},{"issue":"3","key":"735_CR58","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1111\/1759-7714.12421","volume":"8","author":"X Li","year":"2017","unstructured":"Li X, Zhou X, Li Y, Zu L, Pan H, Liu B, et al. Activating transcription factor 3 promotes malignance of lung cancer cells in vitro. Thorac Cancer. 2017;8(3):181\u201391.","journal-title":"Thorac Cancer"},{"issue":"1","key":"735_CR59","first-page":"1","volume":"11","author":"B Ham","year":"2016","unstructured":"Ham B, Fernandez MC, D\u2019Costa Z, Brodt P. The diverse roles of the TNF axis in cancer progression and metastasis. Trends Cancer Res. 2016;11(1):1\u201327.","journal-title":"Trends Cancer Res"},{"issue":"9","key":"735_CR60","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1038\/s41419-020-02923-x","volume":"11","author":"MC Albert","year":"2020","unstructured":"Albert MC, Brinkmann K, Pokrzywa W, G\u00fcnther SD, Kr\u00f6nke M, Hoppe T, et al. CHIP ubiquitylates NOXA and induces its lysosomal degradation in response to DNA damage. Cell Death Dis. 2020;11(9):740.","journal-title":"Cell Death Dis"},{"issue":"3","key":"735_CR61","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1016\/j.celrep.2013.02.014","volume":"3","author":"K Brinkmann","year":"2013","unstructured":"Brinkmann K, Zigrino P, Witt A, Schell M, Ackermann L, Broxtermann P, et al. Ubiquitin C-terminal hydrolase-L1 potentiates cancer chemosensitivity by stabilizing NOXA. Cell Rep. 2013;3(3):881\u201391.","journal-title":"Cell Rep"},{"issue":"4","key":"735_CR62","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1016\/j.febslet.2010.01.026","volume":"584","author":"T Aikawa","year":"2010","unstructured":"Aikawa T, Shinzawa K, Tanaka N, Tsujimoto Y. Noxa is necessary for hydrogen peroxide-induced caspase-dependent cell death. FEBS Lett. 2010;584(4):681\u20138.","journal-title":"FEBS Lett"},{"issue":"11","key":"735_CR63","doi-asserted-by":"publisher","first-page":"1294","DOI":"10.1101\/gad.1304105","volume":"19","author":"SN Willis","year":"2005","unstructured":"Willis SN, Chen L, Dewson G, Wei A, Naik E, Fletcher JI, et al. Proapoptotic Bak is sequestered by Mcl-1 and Bcl-xL, but not Bcl-2, until displaced by BH3-only proteins. Genes Dev. 2005;19(11):1294\u2013305.","journal-title":"Genes Dev"},{"issue":"2","key":"735_CR64","doi-asserted-by":"publisher","DOI":"10.1038\/cddis.2014.6","volume":"5","author":"W Nakajima","year":"2014","unstructured":"Nakajima W, Hicks MA, Tanaka N, Krystal GW, Harada H. Noxa determines localization and stability of MCL-1 and consequently ABT-737 sensitivity in small cell lung cancer. Cell Death Dis. 2014;5(2): e1052.","journal-title":"Cell Death Dis"},{"issue":"2","key":"735_CR65","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1038\/s41418-019-0486-3","volume":"27","author":"VV Senichkin","year":"2020","unstructured":"Senichkin VV, Streletskaia AY, Gorbunova AS, Zhivotovsky B, Kopeina GS. Saga of Mcl-1: regulation from transcription to degradation. Cell Death Differ. 2020;27(2):405\u201319.","journal-title":"Cell Death Differ"},{"issue":"1","key":"735_CR66","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1038\/s41467-017-02693-9","volume":"9","author":"S Zhang","year":"2018","unstructured":"Zhang S, Zhang M, Jing Y, Yin X, Ma P, Zhang Z, et al. Deubiquitinase USP13 dictates MCL1 stability and sensitivity to BH3 mimetic inhibitors. Nat Commun. 2018;9(1):215.","journal-title":"Nat Commun"},{"issue":"10","key":"735_CR67","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1038\/nrc1951","volume":"6","author":"RH Shoemaker","year":"2006","unstructured":"Shoemaker RH. The NCI60 human tumour cell line anticancer drug screen. Nat Rev Cancer. 2006;6(10):813\u201323.","journal-title":"Nat Rev Cancer"},{"issue":"10","key":"735_CR68","doi-asserted-by":"publisher","first-page":"1682","DOI":"10.1021\/np50100a004","volume":"56","author":"GR Pettit","year":"1993","unstructured":"Pettit GR, Pettit GR, Backhaus RA, Boyd MR, Meerow AW. Antineoplastic agents, 256. Cell growth inhibitory isocarbostyrils from Hymenocallis. J Nat Prod. 1993;56(10):1682\u20137.","journal-title":"J Nat Prod"},{"key":"735_CR69","doi-asserted-by":"publisher","first-page":"3083","DOI":"10.3389\/fimmu.2018.03083","volume":"9","author":"H Hu","year":"2018","unstructured":"Hu H, Tian M, Ding C, Yu S. The C\/EBP homologous protein (CHOP) transcription factor functions in endoplasmic reticulum stress-induced apoptosis and microbial infection. Front Immunol. 2018;9:3083.","journal-title":"Front Immunol"},{"issue":"7","key":"735_CR70","doi-asserted-by":"publisher","first-page":"5811","DOI":"10.1074\/jbc.M302637200","volume":"279","author":"PA Townsend","year":"2004","unstructured":"Townsend PA, Scarabelli TM, Davidson SM, Knight RA, Latchman DS, Stephanou A. STAT-1 interacts with p53 to enhance DNA damage-induced apoptosis. J Biol Chem. 2004;279(7):5811\u201320.","journal-title":"J Biol Chem"}],"container-title":["Cellular & Molecular Biology Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s11658-025-00735-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s11658-025-00735-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s11658-025-00735-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T05:01:53Z","timestamp":1747198913000},"score":1,"resource":{"primary":{"URL":"https:\/\/cmbl.biomedcentral.com\/articles\/10.1186\/s11658-025-00735-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,14]]},"references-count":70,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["735"],"URL":"https:\/\/doi.org\/10.1186\/s11658-025-00735-5","relation":{},"ISSN":["1689-1392"],"issn-type":[{"value":"1689-1392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,14]]},"assertion":[{"value":"24 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Animal experiments were reviewed and approved by the Institutional Animal Care and Use Committee (IACUC) of National Cancer Center Research Institute (NCCRI, approval no. NCC-23-884), and the IACUC of NCCRI follows the rules of Basel Declaration. NCCRI is an Association for Assessment and Accreditation of Laboratory Animal Care International (AAALAC International)-accredited facility and abides by the Institute of Laboratory Animal Resources (ILAR) guide.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"59"}}